Company announcement 04/2023.

Roskilde, May 19. 2023

Apillet ApS today announces the first intestinal delivery targets for its APIVault enteric encapsulation material for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.

APIVault is a breakthrough encapsulation material made entirely from natural ingredients: bacterial cellulose and cellulases. We have conducted rigorous laboratory tests and numerical simulations to map the release properties of the combo-material in the intestine. Our results demonstrate that APIVault can deliver compounds reliably in the late small intestine and the colon, using the most suitable cellulases available in the market.

Apillet is currently defining additional development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.